BioSpace News Archive

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent progress and key clinical readouts anticipated in 2020.

To help the fightback against the current Coronavirus outbreak, labs across the globe at the forefront of the scientific response have been sharing genomes and protein structures in open access databases.

Sony Corporation (“Sony”) today announced the launch of KIRAVIA1* Dyes™, a new family of fluorescent dyes, for use in reagents for a wide range of life science applications. Fluorescent reagents are used to study the characteristics of tissues and cells in the life sciences fields, such as immunology and regenerative medicine

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 92,200 shares of the Company’s common stock at an exercise price per share of $18.00, which was the closing price on March 9, 2020

Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named “IMMCELZ™"

The primary mission at Hawkeye Systems, Inc. is to use cutting-edge technology to solve challenging problems thereby bringing strategic value to the customers.

Eyenovia, Inc. announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2019 on Wednesday, March 25, 2020, after the market closes.

Fluidigm’s First Mass Cytometry Center of Excellence in Singapore and Southeast Asia for Advancement of Highly Multiplexed Tissue Imaging in Translational and Clinical Research

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a complete refinancing of its bank debt.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced its financial results for the fourth quarter and full year ended December 31, 2019.